Former Merck Chairman and CEO Roy Vagelos Honored by American Heart Association

For his contributions to improving and saving lives, Dr. Vagelos was honored with the American Heart Association’s Inaugural Lifetime Achievement Award for Research and Science

When former Merck Chairman and CEO P. Roy Vagelos arrived at Merck Research Laboratories in 1975, he brought his experience in cholesterol biosynthesis and a fierce determination to change the course of cardiovascular disease.

During his time at Merck, Dr. Vagelos and his colleagues pioneered treatments for heart disease, high cholesterol and hypertension. For this work and other contributions to improving and saving lives, Dr. Vagelos was honored June 8 with the American Heart Association’s Inaugural Lifetime Achievement Award for Research and Science. Merck Chairman and CEO Ken Frazier presented the award to Dr. Vagelos at the American Heart Association’s event in New York City.

In commenting on his predecessor’s many achievements during his 19 years with the company, Ken noted that Dr. Vagelos had turned Merck “into one of the most powerful and predominant life science companies in the world.” Ken commended Dr. Vagelos for his “enduring commitment to putting patients first,” adding: “And not just those patients who can afford a high standard of medicine. That includes the billions of people who live in circumstances where even the basic necessities are hard to obtain.”

In presenting the award to Dr. Vagelos, Ken said, “Roy’s deep compassion and determination to ensure that scientific innovation thrives for the purpose of saving and improving people’s lives is just one of the many reasons why it is my privilege to present Dr. Roy Vagelos with the American Heart Association’s Inaugural Lifetime Achievement Award for Research and Science.”